Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, Munich, Germany.
Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, Munich, Germany.
Int J Pharm. 2019 Feb 25;557:1-8. doi: 10.1016/j.ijpharm.2018.12.030. Epub 2018 Dec 18.
Lipid-based drug delivery has been investigated for a long time when it comes to liposomes and solid-lipid implants or solid-lipid nanoparticles. The promising, characteristic properties of these systems have led to the development of newer lipid-based drug delivery systems for the sustained release of drugs like liposomes for sustained delivery of substances, DepoFoam™ technology, phospholipid-based phase separation gels and vesicular phospholipid gels. Vesicular phospholipid gels (VPGs) are highly concentrated, viscous dispersions of high amounts of phospholipids in aqueous drug solution. The easy, solvent-free manufacturing process, high biocompatibility and various applications, as depot formulation for the sustained delivery of drugs and as a storage form of small unilamellar vesicles make VPGs highly attractive as drug carriers. Over the last years, the solvent free preparation process has advanced from high pressure homogenization to dual centrifugation (DC). Thereby a very simple one step process has been established for the preparation of VPGs. The semisolid VPG was first described in 1997 by Brandl et al. Since then, many formulations have been developed, encapsulating small molecular weight drugs like 5-FU (2003), cetrorelix (2005), cytarabine (2012) and exenatide (2015). In 2010, the first pharmaceutical protein, erythropoietin, was encapsulated in VPGs and sustained release of the substance was shown in vitro. In 2015, G-CSF was encapsulated in VPGs and tested in vivo for rotator cuff repair in a rat model and for PEGylated IFN-β-1b sustained release from vesicular phospholipid gels was demonstrated in vitro. Further, a very elegant administration technique for VPGs via needle-free injection was established. However this promising drug delivery system does still leave space for improvement and optimization. This review summarizes information about lipid-based depot systems in general and focuses on the historical development of VPGs. It emphasizes the advantages and drawbacks of VPGs as drug delivery device. Additionally, novel preparation methods and applications of VPGs will be discussed. A focus will be set on delivery of pharmaceutical proteins and peptides.
当涉及脂质体和固体制剂或固态脂质纳米粒时,人们已经对基于脂质的药物传递系统进行了很长时间的研究。这些系统具有有前途的特征性质,这导致了开发更新的基于脂质的药物传递系统,以实现药物的缓释,例如脂质体用于物质的缓释,DepoFoam™技术,基于磷脂的相分离凝胶和囊泡磷脂凝胶。囊泡磷脂凝胶(VPG)是高浓度的,高含量磷脂在水性药物溶液中的粘性分散体。易于制备、高生物相容性和各种应用,如药物的缓释储库制剂和小单层囊泡的储存形式,使 VPG 作为药物载体极具吸引力。在过去的几年中,无溶剂制备工艺已经从高压匀浆发展到双离心(DC)。由此,建立了一种非常简单的一步法来制备 VPG。半固态 VPG 于 1997 年由 Brandl 等人首次描述。此后,已经开发了许多制剂,包封了小分子药物,如 5-FU(2003 年)、西曲瑞克(2005 年)、阿糖胞苷(2012 年)和艾塞那肽(2015 年)。2010 年,第一种药物蛋白,促红细胞生成素,被包封在 VPG 中,体外显示了物质的持续释放。2015 年,G-CSF 被包封在 VPG 中,并在大鼠模型中进行了肩袖修复的体内试验,以及体外证明了囊泡磷脂凝胶中 PEG 化 IFN-β-1b 的持续释放。此外,还建立了一种非常优雅的通过无针注射给药的 VPG 技术。然而,这种有前途的药物传递系统仍然有改进和优化的空间。本文综述了一般的基于脂质的储库系统的信息,并重点介绍了 VPG 的历史发展。它强调了 VPG 作为药物传递装置的优缺点。此外,还将讨论 VPG 的新型制备方法和应用。重点将放在药物蛋白和肽的传递上。